Soleno Therapeutics Reports Q4 and FY 2025 Financial Results

What Happened

• Soleno Therapeutics, Inc. (SLNO) filed a Form 8-K on February 25, 2026, to announce and furnish a press release reporting the company's financial results for the quarter and fiscal year ended December 31, 2025. The full press release is attached to the filing as Exhibit 99.1.
• The company states this information is furnished under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: February 25, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Press release attached as Exhibit 99.1 to the Form 8-K.
• The filing notes the information is “furnished” under Item 2.02 and is not “filed” for purposes of Section 18 of the Securities Exchange Act, nor automatically incorporated by reference into other filings.

Why It Matters

• This 8-K signals that Soleno has released its latest earnings and financial condition information—important items (revenue, net income/loss, cash position, guidance) that can affect the stock price and investor decisions.
• Investors should read the attached press release (Exhibit 99.1) and any related filings for the specific financial figures and management commentary, since the Form 8-K itself furnishes the results but does not carry the same Section 18 filing status.